This Plain Language Summary of Publication article (PLSP) from Future Oncology, focused on people with metastatic hormone-sensitive prostate cancer (mHSPC). Before the trial, the standard treatment involved testosterone suppression, and sometimes chemotherapy. Researchers investigated whether adding enzalutamide, an anti-androgen medicine that blocks the effects of testosterone, could improve treatment outcomes.

Visit the site using this link to read the article.

This PLSP is based on three articles called ‘Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer’ published in the New England Journal of Medicine, ‘Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP’ published in the Journal of Clinical Oncology and ‘Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial’ and was published in The Lancet Oncology.

Visit NEJM using the link to read the original article.

Visit ASCO Publications using the link to read the original article.

Visit The Lancet using the link to read the original article.